R323
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 63
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.510
- ALLOGRAFT_REJECTION+0.500
- INTERFERON_GAMMA_RESPONSE+0.450
- INFLAMMATORY_RESPONSE+0.440
- INTERFERON_ALPHA_RESPONSE+0.410
- TNFA_SIGNALING_VIA_NFKB+0.370
- COMPLEMENT+0.360
- KRAS_SIGNALING_UP+0.320
- IL2_STAT5_SIGNALING+0.270
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.200
Top 10 suppressed
- MYC_TARGETS_V2-0.330
- E2F_TARGETS-0.300
- DNA_REPAIR-0.260
- OXIDATIVE_PHOSPHORYLATION-0.210
- MYC_TARGETS_V1-0.190
- MITOTIC_SPINDLE-0.180
- UNFOLDED_PROTEIN_RESPONSE-0.180
- ADIPOGENESIS-0.170
- FATTY_ACID_METABOLISM-0.160
- G2M_CHECKPOINT-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-55-6987-01A-11R-1949-07 | — | cohortMD2 | 0.895 |
| 2 | f26d1599-6e75-4c0d-8b40-c7e45fe9da76 | — | — | 0.889 |
| 3 | sclc0617_S65.txt | — | cohortMD2 | 0.885 |
| 4 | BS_699TN5RN | Ganglioglioma | — | 0.885 |
| 5 | BS_02NZT8CE | low-grade glioma | — | 0.881 |
| 6 | e5b29c06-2ed0-4913-bf24-5bfde047defc | — | — | 0.877 |
| 7 | DRR168509 | — | — | 0.874 |
| 8 | TCGA-55-8208-01A-11R-2241-07 | — | cohortMD2 | 0.874 |
| 9 | SRR1382532 | GTEX | — | 0.865 |
| 10 | TCGA-CN-5369-01A-01R-1436-07 | — | — | 0.864 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.510 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.450 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.440 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.410 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.370 | Inavolisib | — uncovered |
| COMPLEMENT | 0.360 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.320 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.270 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| COAGULATION | 0.180 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.170 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.160 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.130 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| HYPOXIA | 0.090 | Idelalisib | — uncovered |
| MYOGENESIS | 0.080 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.070 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.060 | Inavolisib | — uncovered |